Immutep Completes A$80 Million Capital Raise
27 Giugno 2023 - 2:00PM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the
Company”), a clinical-stage biotechnology company developing novel
LAG-3 immunotherapies for cancer and autoimmune diseases, today
announces the successful completion of an A$80 million capital
raise to support its late-stage and expanding clinical development
pipeline. With this new capital, Immutep believes it is fully
funded for its current and expanded clinical program through to Q1
CY2026 with a pro-forma cash balance of A$135.2 million (US$90.6
million).1
Dr. Russell Howard, Chairman of Immutep, said,
“These funds will help us further our mission to unlock the power
of the immune system to fight cancer and autoimmune disease,
including advancing eftilagimod alpha into a new registrational
Phase III trial in lung cancer, and supporting its late-stage
trials in head and neck cancer and metastatic and triple negative
breast cancer, to final data and Phase II read-outs, respectively.
We’ll also be able to expand eftilagimod alpha into new settings
and potentially conduct a first-in-human Phase I trial for IMP761,
the world’s first and only LAG-3 agonist, for autoimmune diseases.
Our path forward has never been so exciting.”
About ImmutepImmutep is a
clinical stage biotechnology company developing novel LAG-3
immunotherapy for cancer and autoimmune disease. We are pioneers in
the understanding and advancement of therapeutics related to
Lymphocyte Activation Gene-3 (LAG-3), and our diversified product
portfolio harnesses its unique ability to stimulate or suppress the
immune response. Immutep is dedicated to leveraging its expertise
to bring innovative treatment options to market for patients in
need and to maximise value for shareholders. For more information,
please visit www.immutep.com.
U.S.
Investors/Media:Chris Basta, VP,
Investor Relations and Corporate Communications+1 (631) 318 4000;
chris.basta@immutep.com
This Media Release does not constitute an offer
to sell, or a solicitation of an offer to buy, securities in the
United States. The securities sold in Immutep’s capital raise
discussed in this Media Release have not been, and will not be,
registered under the U.S. Securities Act of 1933 (the
Securities Act) or the securities
laws of any state or other jurisdiction of the United States, Such
securities may not be offered or sold in the United States except
in a transaction registered under the Securities Act or pursuant to
an exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act and applicable U.S.
state securities laws.
1 Based on cash balance as at 31 March 2023 and completion of an
A$80m capital raising, excluding offer costs.
Grafico Azioni Immutep (NASDAQ:IMMP)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Immutep (NASDAQ:IMMP)
Storico
Da Mag 2023 a Mag 2024